The six-month results from the single-arm TRILUMINATE Feasibility trial confirm Abbott Laboratories Inc.’s TriClip, a tricuspid version of Abbott’s MitraClip mitral valve repair device, improves both clinical endpoints and quality of life for patients with tricuspid regurgitation.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?